<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3161761</article-id><article-id pub-id-type="publisher-id">PONE-D-10-06550</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0023924</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Cytochemistry</subject><subj-group><subject>In Situ Hybridization</subject></subj-group></subj-group></subj-group><subj-group><subject>Genetics</subject><subj-group><subject>Cancer Genetics</subject></subj-group></subj-group><subj-group><subject>Genomics</subject><subj-group><subject>Genome Analysis Tools</subject><subject>Structural Genomics</subject></subj-group></subj-group><subj-group><subject>Molecular Cell Biology</subject><subj-group><subject>Signal Transduction</subject><subj-group><subject>Signaling in Selected Disciplines</subject><subj-group><subject>Oncogenic Signaling</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Pancreas</subject></subj-group></subj-group><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Gastrointestinal Tumors</subject><subj-group><subject>Pancreatic Cancer</subject></subj-group></subj-group></subj-group><subj-group><subject>Basic Cancer Research</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title><italic>SMURF1</italic> Amplification Promotes Invasiveness in Pancreatic Cancer</article-title><alt-title alt-title-type="running-head"><italic>SMURF1</italic> Amplification in Pancreatic Cancer</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kwei</surname><given-names>Kevin A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Shain</surname><given-names>A. Hunter</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bair</surname><given-names>Ryan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Montgomery</surname><given-names>Kelli</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Karikari</surname><given-names>Collins A.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>van de Rijn</surname><given-names>Matt</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hidalgo</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maitra</surname><given-names>Anirban</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bashyam</surname><given-names>Murali D.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pollack</surname><given-names>Jonathan R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Pathology, Stanford University, Stanford, California, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Clinical Research Program, Centro Nacional de Investigaciones Oncol&#x000f3;gicas, Madrid, Spain</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Laboratory of Molecular Oncology, Centre for DNA Fingerprinting and Diagnostics, Nampally, Hyderabad, India</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Alg&#x000fc;l</surname><given-names>Hana</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Technische Universit&#x000e4;t M&#x000fc;nchen, Germany</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>pollack1@stanford.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: KAK AHS JRP. Performed the experiments: KAK AHS RB MDB. Analyzed the data: KAK AHS JRP. Contributed reagents/materials/analysis tools: KM CAK MvdR MH AM. Wrote the paper: KAK AHS JRP.</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>22</day><month>8</month><year>2011</year></pub-date><volume>6</volume><issue>8</issue><elocation-id>e23924</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2010</year></date><date date-type="accepted"><day>1</day><month>8</month><year>2011</year></date></history><permissions><copyright-statement>Kwei et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2011</copyright-year></permissions><abstract><p>Pancreatic cancer is a deadly disease, and new therapeutic targets are urgently needed. We previously identified DNA amplification at 7q21-q22 in pancreatic cancer cell lines. Now, by high-resolution genomic profiling of human pancreatic cancer cell lines and human tumors (engrafted in immunodeficient mice to enrich the cancer epithelial fraction), we define a 325 Kb minimal amplicon spanning <italic>SMURF1</italic>, an E3 ubiquitin ligase and known negative regulator of transforming growth factor &#x003b2; (TGF&#x003b2;) growth inhibitory signaling. <italic>SMURF1</italic> amplification was confirmed in primary human pancreatic cancers by fluorescence <italic>in situ</italic> hybridization (FISH), where 4 of 95 cases (4.2&#x00025;) exhibited amplification. By RNA interference (RNAi), knockdown of SMURF1 in a human pancreatic cancer line with focal amplification (AsPC-1) did not alter cell growth, but led to reduced cell invasion and anchorage-independent growth. Interestingly, this effect was not mediated through altered TGF&#x003b2; signaling, assayed by transcriptional reporter. Finally, overexpression of SMURF1 (but not a catalytic mutant) led to loss of contact inhibition in NIH-3T3 mouse embryo fibroblast cells. Together, these findings identify <italic>SMURF1</italic> as an amplified oncogene driving multiple tumorigenic phenotypes in pancreatic cancer, and provide a new druggable target for molecularly directed therapy.</p></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Pancreatic ductal adenocarcinoma (hereafter, pancreatic cancer) is nearly always fatal, with a five year survival rate less than 5&#x00025; <xref ref-type="bibr" rid="pone.0023924-Jemal1">[1]</xref>. It is often disseminated at diagnosis, and can metastasize widely. Early detection can improve survival, but surgical resection is rarely curative <xref ref-type="bibr" rid="pone.0023924-Li1">[2]</xref>. Pancreatic cancer is also largely resistant to conventional chemotherapy. Therefore, new therapies are urgently needed. In particularly, it will be important to discover and validate new targets for molecularly-directed therapy.</p><p>The molecular genetics of pancreatic cancer are in part known <xref ref-type="bibr" rid="pone.0023924-Hezel1">[3]</xref>, <xref ref-type="bibr" rid="pone.0023924-Hruban1">[4]</xref>. Somatic activating mutations of <italic>KRAS</italic> (sometimes occurring with gene amplification) are found in &#x0003e;90&#x00025; of pancreatic cancers. Also common are inactivating mutations/deletions of tumor suppressors <italic>CDKN2A</italic> (&#x0003e;95&#x00025; of cancers), <italic>TP53</italic> (50&#x02013;75&#x00025;), and <italic>SMAD4</italic> (also known as <italic>DPC4</italic>) (55&#x00025;), an effector of TGF&#x003b2;-mediated growth inhibition. Other gene mutations, each occurring in less than 5&#x00025; of cancers, impact these and other core cancer signaling pathways <xref ref-type="bibr" rid="pone.0023924-Jones1">[5]</xref>.</p><p>Genomic profiling studies, by array-based comparative genomic hybridization (array CGH), have begun to catalogue DNA amplifications and deletions, pinpointing and revealing novel pancreatic cancer genes (e.g. <xref ref-type="bibr" rid="pone.0023924-Kwei1">[6]</xref>, <xref ref-type="bibr" rid="pone.0023924-Chen1">[7]</xref>). Among altered loci, we and others previously identified 7q21-q22 as a site recurrently amplified in pancreatic cancer <xref ref-type="bibr" rid="pone.0023924-Aguirre1">[8]</xref>&#x02013;<xref ref-type="bibr" rid="pone.0023924-Loukopoulos1">[13]</xref>. Here, we narrow that locus, and characterize SMURF1 as an oncogene product promoting cell invasion and anchorage-independent growth.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title><italic>SMURF1</italic> is focally amplified in pancreatic cancer</title><p>We had previously identified recurrent amplification at 7q21-q22 in pancreatic cancer cell lines, using CGH on cDNA microarrays <xref ref-type="bibr" rid="pone.0023924-Bashyam1">[12]</xref>. To further delimit the amplicon, and pinpoint the resident oncogene(s), we now carried out additional genomic profiling of a collection of 22 pancreatic cancer cell lines and 58 early-passage pancreatic cancer xenografts, using high-resolution 244K Agilent CGH arrays. The 7q21-q22 locus was focally amplified (tumor/normal ratios &#x0003e;3-fold) in 1 of 22 (4.5&#x00025;) cell lines (AsPC-1), and in 1 of 58 (2&#x00025;) xenografts. Including lower-level gains (ratios &#x0003e;1.3 fold), gain/amplification spanning 7q21-q22 was found in 6 of 22 (27&#x00025;) cell lines, and in 19 of 58 (33&#x00025;) xenografts.</p><p>Four specimens (the AsPC-1 cell line, and three xenografts) had genomic profiles that were particularly informative in delimiting the amplicon boundaries within 7q21-q22 (<xref ref-type="fig" rid="pone-0023924-g001">Fig. 1A</xref>). The smallest common region of gain spanned just 325 Kb within cytoband 7q22.1, and contained just two RefSeq <xref ref-type="bibr" rid="pone.0023924-Pruitt1">[14]</xref> genes, <italic>SMURF1</italic> (SMAD specific E3 ubiquitin protein ligase) and <italic>KPNA7</italic> (karyopherin alpha 7). SMURF1 is a known inhibitor of TGF&#x003b2; signaling (by promoting degradation of its receptor TGF&#x003b2;RI, and signaling mediator SMAD4 <xref ref-type="bibr" rid="pone.0023924-Ebisawa1">[15]</xref>, <xref ref-type="bibr" rid="pone.0023924-Moren1">[16]</xref>), a pathway frequently disrupted in pancreatic cancer. Given an obvious connection to pancreatic carcinogenesis, we therefore focused subsequent efforts on <italic>SMURF1</italic>.</p><fig id="pone-0023924-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0023924.g001</object-id><label>Figure 1</label><caption><title>Focal amplification of 7q22.1 in pancreatic cancer spans <italic>SMURF1</italic>.</title><p>(<bold>A</bold>) A minimal amplicon is defined by four pancreatic cancer specimens (AsPC-1 and three xenografts). Starting from bottom: chr 7 ideogram; Heatmap of DNA copy number (red indicates gain) for the four specimens across the 7q21-q22 region (91&#x02013;101 Mb); Scatter plot of DNA copy number log<sub>2</sub> ratios across 7q21.3-q22.1 (96&#x02013;100 Mb), overlaid with the cghFLasso <xref ref-type="bibr" rid="pone.0023924-Tibshirani1">[34]</xref> called ratios (red line); Screen shot of the corresponding locus from the UCSC genome browser. The dashed lines bracket the 325 Kb minimal amplicon, which spans <italic>SMURF1</italic>. (<bold>B</bold>) <italic>SMURF1</italic> is overexpressed when gained/amplified. Box plots show 25<sup>th</sup>, 50<sup>th</sup> (median) and 75<sup>th</sup> percentile transcript levels (assayed by Agilent 44K array) for specimens with (red) or without (gray) 7q21-q22 gain, for <italic>SMURF1</italic> and its nearest gene neighbors. Note, <italic>KPNA7</italic> was not represented on the array. &#x0002a;, <italic>P</italic>&#x0003c;0.05; &#x0002a;&#x0002a;, <italic>P</italic>&#x0003c;0.01; &#x0002a;&#x0002a;&#x0002a;, <italic>P</italic>&#x0003c;0.001 (Mann-Whitney U-test). (<bold>C</bold>) FISH reveals <italic>SMURF1</italic> amplification in primary pancreatic cancers. Shown are two pancreatic cancers with <italic>SMURF1</italic> amplification (<italic>center</italic>, and <italic>right</italic>), along with a non-amplified control (BxPC3 cells, <italic>left</italic>). <italic>SMURF1</italic> locus probe (red); control chr 7 centromere (CRP7) probe (green).</p></caption><graphic xlink:href="pone.0023924.g001"/></fig><p>Consistent with an oncogenic role, <italic>SMURF1</italic> transcript (measured by microarray) was significantly elevated in cell lines/xenografts with 7q22.1 gain/amplification (as were several co-amplified neighboring genes) (<xref ref-type="fig" rid="pone-0023924-g001">Fig. 1B</xref>). To evaluate <italic>SMURF1</italic> amplification in primary pancreatic tumors, we also carried out FISH on a tissue microarray containing 105 pancreatic cancer cases. Four of 95 (4.2&#x00025;) evaluable cases exhibited <italic>SMURF1</italic> amplification (locus/centromere ratio &#x0003e;2.5) (<xref ref-type="fig" rid="pone-0023924-g001">Fig. 1C</xref>), comparable to our CGH findings for early-passage xenografts. We were unable to identify a suitable antibody and staining conditions to evaluate SMURF1 expression by immunohistochemistry.</p></sec><sec id="s2b"><title><italic>SMURF1</italic> amplification promotes cell invasion and anchorage-independent growth</title><p>To evaluate possible oncogenic functions of SMURF1, we first used RNAi to knockdown SMURF1 expression in the relevant context of gene amplification, using AsPC-1 cells. Transfection of four different small interfering RNAs (siRNAs), or a pool of the four together, each led to reduced SMURF1 protein levels (by Western blot), compared to a non-targeting siRNA pool (<xref ref-type="fig" rid="pone-0023924-g002">Fig. 2A</xref>). Knockdown of SMURF1 did not alter cell proliferation, measured by WST-1 assay (<xref ref-type="fig" rid="pone-0023924-g002">Fig. 2B,C</xref>), and by BrdU incorporation (<xref ref-type="fig" rid="pone-0023924-g002">Fig. 2D</xref>), but led to significantly decreased cell invasion through Matrigel, measured by Boyden chamber assay (<xref ref-type="fig" rid="pone-0023924-g002">Fig. 2E</xref>). Decreased invasion was seen with each of the four siRNAs targeting distinct <italic>SMURF1</italic> sequences, while the growth rate of the cells remained unchanged within the same time period (<xref ref-type="fig" rid="pone-0023924-g002">Fig. 2C</xref>), strongly supporting the specific role of SMURF1 in the invasiveness phenotype.</p><fig id="pone-0023924-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0023924.g002</object-id><label>Figure 2</label><caption><title>SMURF1 knockdown in amplified AsPC-1 cells reduces invasion but not growth.</title><p>(<bold>A</bold>) Four different siRNAs targeting <italic>SMURF1</italic>, and a pool of all four, lead to reduced SMURF1 levels (by Western blot) compared to a non-targeting control siRNA pool). Residual SMURF1 levels, here normalized to GAPDH, are indicated. (<bold>B</bold>) SMURF1 knockdown (using siRNA pool) does not reduce cell proliferation/viability, measured by WST1 assay, and done in triplicate (mean &#x0002b;/&#x02212; 1SD shown). (<bold>C</bold>) SMURF1 knockdown using four different siRNAs does not significantly alter cell proliferation/viability, measured three days post transfection. Done in triplicate (mean &#x0002b;/&#x02212; 1SD shown). (<bold>D</bold>) SMURF1 knockdown does not reduce cell-cycle progression (S-phase), measured by BrdU incorporation (1.5 hr and 4 hr pulse labeling), done in triplicate (mean &#x0002b;/&#x02212; 1 SD shown). (<bold>E</bold>) SMURF1 knockdown (using siRNA pool and individual siRNAs) inhibits cell invasion through Matrigel. Boyden chamber assay done in triplicate and harvested three days post transfection (mean &#x0002b;/&#x02212; 1SD shown); &#x0002a;, <italic>P</italic>&#x0003c;0.05 (Student's t-test). (<bold>F</bold>) SMURF1 knockdown does not enhance TGF&#x003b2; pathway-mediated transcription. AsPC-1 cells were co-transfected with siRNAs and p3TP-Lux reporter, done in triplicate, and firefly/Renilla luciferase ratios shown (mean &#x0002b;/&#x02212; 1SD shown). Panc1 cells (with wildtype <italic>SMAD4</italic>) &#x0002b;/&#x02212; TGF&#x003b2; serve as a positive control.</p></caption><graphic xlink:href="pone.0023924.g002"/></fig><p>Given its known, antagonistic function in the TGF&#x003b2; pathway, we also sought to evaluate the effect of SMURF1 knockdown on TGF&#x003b2; signaling, using a TGF&#x003b2; responsive transcriptional reporter (p3TP-Lux) <xref ref-type="bibr" rid="pone.0023924-Wrana1">[17]</xref>. Knockdown of SMURF1 did not enhance TGF&#x003b2; pathway-mediated transcription in AsPC-1 cells (<xref ref-type="fig" rid="pone-0023924-g002">Fig. 2F</xref>). Of note, however, AsPC-1 cells (like most pancreatic cancers) harbor a mutated <italic>SMAD4</italic>, here SMAD4 (R100T) <xref ref-type="bibr" rid="pone.0023924-Schutte1">[18]</xref>, characterized to be inactivating <xref ref-type="bibr" rid="pone.0023924-Dai1">[19]</xref>, <xref ref-type="bibr" rid="pone.0023924-Wan1">[20]</xref>. Therefore, AsPC-1 cells are likely incapable of a TGF&#x003b2; pathway transcriptional response. More generally, these findings suggest that the main effect(s) of <italic>SMURF1</italic> amplification/overexpression are likely mediated through pathways distinct from TGF&#x003b2; signaling.</p><p>To evaluate longer-term phenotypes, we also stably transfected a short hairpin RNA (shRNA) targeting <italic>SMURF1</italic>. Stable knockdown of SMURF1 in AsPC-1 cells, confirmed by Western blot (<xref ref-type="fig" rid="pone-0023924-g003">Fig. 3A</xref>), significantly reduced anchorage independent growth (soft agar colonies), compared to a non-targeting shRNA control (<xref ref-type="fig" rid="pone-0023924-g003">Fig. 3B</xref>).</p><fig id="pone-0023924-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0023924.g003</object-id><label>Figure 3</label><caption><title>Knockdown of amplified <italic>SMURF1</italic> in AsPC-1 cells reduces anchorage-independent growth.</title><p>(<bold>A</bold>) A stably transduced shRNA targeting SMURF1 leads to reduced SMURF1 levels (by Western blot) compared to a non-targeting control shRNA. Residual SMURF1 levels, here normalized to GAPDH, are indicated. (<bold>B</bold>) Stable SMURF1 knockdown reduces anchorage-independent growth (i.e. soft agar colonies). Assay done in triplicate (mean &#x0002b;/&#x02212; 1SD shown); &#x0002a;, <italic>P</italic>&#x0003c;0.05 (Student's t-test).</p></caption><graphic xlink:href="pone.0023924.g003"/></fig><p>We also sought to evaluate the effect of siRNA knockdown in other pancreatic cancer cell lines. We chose two cell lines, BxPC-3 cells which (like AsPC-1 cells and most pancreatic tumors) have mutated <italic>SMAD4</italic> (here by homozygous deletion) <xref ref-type="bibr" rid="pone.0023924-Hahn1">[21]</xref>, and Hs700T cells which are wildtype for <italic>SMAD4</italic> and have an intact TGF&#x003b2; growth-inhibitory pathway (<xref ref-type="supplementary-material" rid="pone.0023924.s002">Fig. S1</xref>). Notably, neither of these lines harbors focal amplification of <italic>SMURF1</italic> (AsPC-1 cells are the only established line with focal amplification), nor elevated SMURF1 protein levels (<xref ref-type="fig" rid="pone-0023924-g004">Fig. 4A</xref>). Knockdown of SMURF1 (validated by Western blot; <xref ref-type="fig" rid="pone-0023924-g004">Fig. 4B</xref>) led to modestly reduced cell proliferation in BxPC-3 cells (<xref ref-type="fig" rid="pone-0023924-g004">Fig. 4C</xref>), and more so in TGF&#x003b2;-growth inhibitory pathway-intact Hs700T cells (<xref ref-type="fig" rid="pone-0023924-g004">Fig. 4D</xref>). SMURF1 knockdown also resulted in reduced cell invasion in BxPC-3 cells (<xref ref-type="fig" rid="pone-0023924-g004">Fig. 4E</xref>), though not significantly so. However, given that <italic>SMURF1</italic> is neither focally amplified nor overexpressed in these lines, a simple explanation for the discordant phenotypes (compared to AsPC-1) is that SMURF1 may not function as an oncogenic driver in these cell contexts.</p><fig id="pone-0023924-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0023924.g004</object-id><label>Figure 4</label><caption><title>Analysis of SMURF1 knockdown in other pancreatic cancer lines.</title><p>(<bold>A</bold>) Western blot analysis of endogenous SMURF1 protein levels in a panel of pancreatic cancer cell lines. Note that SMURF1 is highly expressed only in the 7q22.1-amplified AsPC-1 cell line. Two different exposures of the SMURF1 blot are shown; GAPDH serves as a loading control. (<bold>B</bold>) Western blot verification of SMURF1 knockdown (by SMURF1-targeting siRNA pool, compared to non-targeting control siRNA pool) in BxPC-3 and Hs700T cells. (<bold>C</bold>) Cell proliferation/viability assayed (by WST-1) in BxPC-3 cells following SMURF1 siRNA-mediated knockdown (compared to non-targeting control). Assay done in triplicate (mean &#x0002b;/&#x02212; 1SD shown); &#x0002a;, <italic>P</italic>&#x0003c;0.05 (Student's t-test). (<bold>D</bold>) Cell proliferation/viability assayed in Hs700T cells, as above. (<bold>E</bold>) Cell invasion assayed (by Boyden chamber) in BxPC-3 cells following SMURF1 knockdown (compared to non-targeting control). Assay done in triplicate (mean &#x0002b;/&#x02212; 1SD shown). Note, the reduced proliferation observed with SMURF1 knockdown in Hs700T cells precluded an assay of cell invasion (where invaded cell numbers at 72 hrs are influenced by doubling times).</p></caption><graphic xlink:href="pone.0023924.g004"/></fig><p>Finally, in complementary, overexpression studies, we transfected <italic>SMURF1</italic> cDNA (expressed from a CMV promoter) into NIH-3T3 mouse fibroblasts. Overexpression of SMURF1, confirmed by Western blot (<xref ref-type="fig" rid="pone-0023924-g005">Fig. 5A</xref>), led to a significant loss of contact inhibition (i.e. increased foci), compared to a vector control (<xref ref-type="fig" rid="pone-0023924-g005">Fig. 5B</xref>). Notably, transfection of a catalytically-inactive mutant of SMURF1 (C699A) <xref ref-type="bibr" rid="pone.0023924-Wang1">[22]</xref> did not reduce contact inhibition (<xref ref-type="fig" rid="pone-0023924-g004">Fig. 4B</xref>), indicating that this oncogenic activity is dependent on the E3 ubiquitin protein ligase activity of SMURF1.</p><fig id="pone-0023924-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0023924.g005</object-id><label>Figure 5</label><caption><title>SMURF1 overexpression in NIH-3T3 cells leads to loss of contact inhibition.</title><p>(<bold>A</bold>) Transfection of SMURF1 cDNA, or a catalytic mutant of SMURF1 (C699A) (SMURF1<sup>m</sup>), leads to overexpression (by Western blot) compared to empty vector control. SMURF1 overexpression levels, normalized to GAPDH, are indicated. (<bold>B</bold>) SMURF1 (but not SMURF1<sup>m</sup>) overexpression in NIH-3T3 cells leads to loss of contact inhibition (i.e. increased foci formation). Assays done in triplicate (mean &#x0002b;/&#x02212; 1SD shown); &#x0002a;, <italic>P</italic>&#x0003c;0.05 (Student's t-test).</p></caption><graphic xlink:href="pone.0023924.g005"/></fig></sec></sec><sec id="s3"><title>Discussion</title><p>Here, we set out to pinpoint and discover the oncogene driving 7q21-q22 amplification in pancreatic cancer. High-resolution genomic profiling of pancreatic cancer cell lines and early-passage xenografts defined a 325 Kb minimal amplicon spanning <italic>SMURF1</italic>. Transcript levels of <italic>SMURF1</italic> were elevated in specimens with gain/amplification, and by FISH we confirmed <italic>SMURF1</italic> amplification in primary pancreatic cancers. Using complementary approaches of knockdown (in focally-amplified AsPC-1 cells) and overexpression (in NIH-3T3 cells), we determined that <italic>SMURF1</italic> amplification/overexpression does not alter cell proliferation, but promotes cell invasion, anchorage-independent growth, and loss of contact inhibition, of which at least the latter is dependent on its catalytic activity.</p><p>SMURF1 was initially an intriguing oncogene candidate because of its known connection to TGF&#x003b2; signaling. The TGF&#x003b2; pathway, at least early in tumor development, is growth suppressive <xref ref-type="bibr" rid="pone.0023924-Massague1">[23]</xref>. Normally, TGF&#x003b2; binds to its receptors (TGF&#x003b2;RI, TGF&#x003b2;RII), leading to the phosphorylation of signal transducers SMAD2/SMAD3, which then shuttle to the nucleus and in complex with SMAD4 mediate transcription. Key transcriptional responses include induction of <italic>CDKN2B</italic> (p15Ink4b) and <italic>CDKN1A</italic> (p21Cip1), and repression of <italic>MYC</italic>, together leading to G<sub>1</sub> cell-cycle arrest. The TGF&#x003b2; growth suppressive pathway is commonly disrupted in pancreatic cancer, most often through mutation/deletion of <italic>SMAD4</italic>, but also through inactivation/loss of <italic>TGF&#x003b2;RI</italic> and <italic>TGF&#x003b2;RII</italic> <xref ref-type="bibr" rid="pone.0023924-Hruban1">[4]</xref>.</p><p>SMURF1 is a HECT-domain E3 ubiquitin ligase (E3 ubiquitin ligases carry out the third and substrate-specific step in protein ubiquitination). SMURF1 promotes the nuclear export of TGF&#x003b2; pathway inhibitor SMAD7 (increasing its availability), and the destruction of TGF&#x003b2;RI and SMAD4 (through ubiquitination-mediated degradation) <xref ref-type="bibr" rid="pone.0023924-Ebisawa1">[15]</xref>, <xref ref-type="bibr" rid="pone.0023924-Moren1">[16]</xref>. All these activities should serve to antagonize TGF&#x003b2; signaling, and together provide a strong rationale for <italic>SMURF1</italic> amplification/overexpression in pancreatic cancer. It was notable then, that SMURF1 knockdown in AsPC-1 cells did not enhance TGF&#x003b2;-pathway transcription (though perhaps not surprising, given the inactivating mutation of <italic>SMAD4</italic>). Therefore, the oncogenic activities of SMURF1 must act at least in part independently of its functions in TGF&#x003b2; signaling (at least at the pathway level of SMAD4). To this end, SMURF1 has also been shown to dissolve tight junctions (by degradation of RhoA) during epithelial-mesenchymal transition <xref ref-type="bibr" rid="pone.0023924-Ozdamar1">[24]</xref>, and focal adhesions (by degradation of talin heads) to potentiate cell migration <xref ref-type="bibr" rid="pone.0023924-Huang1">[25]</xref>. Additional studies should clarify the key SMURF1 substrates linked to invasiveness and anchorage-independent growth in pancreatic cancers with 7q22 amplification.</p><p>During the progress of this work, two other studies characterized the 7q21-q22 amplicon in pancreatic cancer. Suzuki <italic>et al.</italic> <xref ref-type="bibr" rid="pone.0023924-Suzuki1">[26]</xref> by genomic profiling of cell lines identified the amplicon in AsPC-1 cells, with the amplicon peak spanning 11 genes. Further efforts focused on two genes, <italic>TRRAP</italic> and <italic>SMURF1</italic>, with significantly elevated expression when amplified. However, in contrast to our study, they reported that knockdown of SMURF1 inhibited AsPC-1 cell proliferation. Notably, though, they evaluated only one siRNA. Given our results that four independent siRNAs knocked down SMURF1 levels comparably and decreased invasion without affecting cell proliferation, we suggest that their finding might reflect a non-specific or specific off-target RNAi effect. Indeed, growth inhibition is a common non-specific effect, triggered by a type I interferon response to siRNA <xref ref-type="bibr" rid="pone.0023924-Sledz1">[27]</xref>. Suzuki <italic>et al.</italic> went on to show that SMURF1 overexpression in two pancreatic cancer cell lines enhanced colony growth on tissue culture plastic. Nonetheless, our findings based on knockdown in the physiologically-relevant context of focal <italic>SMURF1</italic> amplification suggest that the main oncogenic function of SMURF1 relates to promoting cell invasiveness rather than proliferation.</p><p>In another recent study, Laurila <italic>et al.</italic> <xref ref-type="bibr" rid="pone.0023924-Laurila1">[28]</xref> by FISH analysis of cell lines delimited the 7q21-q22 amplicon to 0.77 Mb spanning 10 genes (including <italic>SMURF1</italic>), but focused their efforts on <italic>ARPC1A</italic> and <italic>ARPC1B</italic>, subunits of the Arp2/3 complex functioning in actin polymerization. Using RNAi, they found that knockdown of either reduced cell motility, and knockdown of <italic>ARPC1A</italic> also reduced cell invasion. Though our minimal amplicon excluded <italic>ARPC1A</italic> and <italic>ARPC1B</italic>, it is nonetheless possible that their amplification contributes to motility/invasion in tumors where they are amplified. It is not uncommon to find multiple driver oncogenes within tumor amplicons (e.g. ref. <xref ref-type="bibr" rid="pone.0023924-Kao1">[29]</xref>). Indeed, our own studies do not resolve whether <italic>KPNA7</italic>, within our 325 Kb minimal amplicon, might also have an oncogenic role (along with <italic>SMURF1</italic>).</p><p>To summarize, by genomic profiling and functional analysis we identified <italic>SMURF1</italic> as an amplified oncogene driving cell invasiveness in pancreatic cancer. Perhaps of most significance, as an enzyme SMURF1 represents a tractable drug target. Other E3 ubiquitin ligases have been linked to cancer, and because of their substrate specificity E3 ubiquitin ligases are thought to be attractive targets for therapy <xref ref-type="bibr" rid="pone.0023924-Chen2">[30]</xref>. Indeed, several small molecule inhibitors (including against MDM2, a regulator of TP53) are presently being evaluated <xref ref-type="bibr" rid="pone.0023924-Guedat1">[31]</xref>. Our findings identify SMURF1 as a possible new target for molecularly-directed therapy against the devastating disease of pancreatic cancer.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Specimens</title><p>Pancreatic cancer cell lines, described previously <xref ref-type="bibr" rid="pone.0023924-Bashyam1">[12]</xref>, and NIH-3T3 cells were obtained from the American Type Culture Collection (Manassas, VA). Pancreatic cancer xenografts, which effectively enrich the tumor epithelial fraction for DNA analysis, were generated as described <xref ref-type="bibr" rid="pone.0023924-Hahn2">[32]</xref> at the Johns Hopkins Hospital, with approval from the Institutional Review Board (IRB) (protocol ID 05-04-14-02) and Animal Care and Use Committee (protocol ID MO05M466). Briefly, a 1 mm<sup>3</sup> piece of the primary tumor was soaked in Matrigel (Collaborative Biomedical Research), then implanted subcutaneously in a nu/nu mouse. Engrafted tumors were harvested when they reached 1&#x02013;2 cm in diameter, and tumor cell enrichment confirmed by H&#x00026;E-stained frozen section. DNA and RNA were isolated using the Qiagen (Valencia, CA) AllPrep kit. Eleven of the 48 xenografts were previously profiled by lower-resolution CGH on cDNA arrays <xref ref-type="bibr" rid="pone.0023924-Kwei1">[6]</xref>.</p></sec><sec id="s4b"><title>Array CGH</title><p>CGH was done using Agilent (Santa Clara, CA) catalogue 244K CGH arrays. DNAs were labeled as described <xref ref-type="bibr" rid="pone.0023924-Pollack1">[33]</xref>, then hybridized (<italic>vs.</italic> a pool of eight sex-matched normal leukocyte DNAs) following the manufacturer's instructions. Arrays were scanned using an Agilent G2505B scanner, and data extracted and normalized using Agilent Feature Extraction software (version 9.1) with default settings. Copy number alterations were called using cghFLasso <xref ref-type="bibr" rid="pone.0023924-Tibshirani1">[34]</xref>, and low-level gains and higher-level amplifications defined by cghFLasso tumor/normal ratios &#x0003e;1.3 and &#x0003e;3.0, respectively. CGH data detailed herein are available at GEO (GSE19852); a complete description of the dataset is in preparation.</p></sec><sec id="s4c"><title>Expression profiling</title><p>Expression profiling was done using Agilent catalogue 44K Whole Human Genome arrays. RNAs were labeled using the Quick Amp Labeling kit (Agilent), then hybridized (<italic>vs.</italic> a universal RNA reference pool of 11 cancer cell lines <xref ref-type="bibr" rid="pone.0023924-Perou1">[35]</xref>) following the manufacturer's instructions. After scanning and data extraction (as above), expression data were normalized (mean-centered) by array and by gene, and mean-centered log<sub>2</sub> ratios reported.</p></sec><sec id="s4d"><title>FISH</title><p>A tissue microarray containing 105 pancreatic ductal adenocarcinoma cases (archived at Stanford University, and used with IRB approval) was previously described <xref ref-type="bibr" rid="pone.0023924-Kwei1">[6]</xref>. Probe labeling and FISH were performed using Vysis (Downers Grove, Illinois) reagents according to the manufacturer's protocols. A locus-specific BAC mapping to <italic>SMURF1</italic> at 7q22.1 (RP11-62N3; BACPAC Resources Centre, Oakland, CA) was labeled with SpectrumOrange, and co-hybridized with SpectrumGreen-labeled chr 7 centromere probe (CEP7; Vysis). Slides were counterstained with DAPI, and imaged using an Olympus BX51 fluorescence microscope with Applied Imaging (San Jose, CA) Cytovision 3.0 software. Twenty-five tumor cells were scored per case, and amplification defined as an average <italic>SMURF1</italic>/CEP7 ratio &#x0003e;2.5.</p></sec><sec id="s4e"><title>siRNA transfections</title><p>On-TARGETplus siRNAs targeting <italic>SMURF1</italic>, along with a negative control siRNA pool (ON-TARGETplus siCONTROL Non-targeting Pool), were obtained from Dharmacon (Lafayette, CO). Sequences of siRNAs are listed in <xref ref-type="supplementary-material" rid="pone.0023924.s001">Table S1</xref>. AsPC-1 cells were grown at 37&#x000b0;C in complete media of RPMI-1640 (Invitrogen, Carlsbad, CA), 10&#x00025; FBS, 50 U/ml penicillin, and 50 U/ml streptomycin. For transfection, 150,000 cells were seeded per 6-well plate well, and transfected using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol. Cells were transfected with a final concentration of 50 nM siRNA for 6 hrs.</p></sec><sec id="s4f"><title>Western blot</title><p>Cells were lysed in 1&#x000d7; RIPA buffer supplemented as described <xref ref-type="bibr" rid="pone.0023924-Kwei1">[6]</xref>. Forty &#x000b5;g total protein lysate was electrophoresed on a 4&#x02013;15&#x00025; polyacrylamide gel, then transferred to PVDF membrane and blocked in TBST-T with 5&#x00025; dry milk. Antibodies were used as follows: anti-SMURF1 rabbit polyclonal antibody (H-60; Santa Cruz Biotechnology, Santa Cruz, CA) at 1&#x02236;500 dilution; anti-GAPDH rabbit polyclonal antibody (Santa Cruz Biotechnology) at 1&#x02236;5,000 dilution; HRP-conjugated anti-rabbit IgG (Pierce, Rockford, IL) at 1&#x02236;20,000 dilution. Detection was done using an ECL kit (GE Healthcare, Piscataway, NJ), and intensities quantified by densitometry using Scion Image software (Scion Corporation, Fredrick, MD).</p></sec><sec id="s4g"><title>Cell growth and invasion assays</title><p>Cell proliferation/viability was quantified by colorimetry based on the metabolic cleavage of the tetrazolium salt WST-1 in viable cells, according to the manufacturer's protocol (Roche, Indianapolis, IN). BrdU incorporation was determined by colorimetric ELISA using the BrdU Cell Proliferation Assay, according to the manufacturer's protocol (Cell Signaling Technology, Danvers, MA). Invasion was quantified by Boyden chamber assay (BD Biosciences, San Jose, CA). Briefly, 24 hrs after transfection, 50,000 cells were plated into 24-well Matrigel-coated inserts with a 0.5&#x00025; to 10&#x00025; FBS gradient. Seventy-two hrs later, cells were fixed, stained with crystal violet, and cells traversing the membrane counted. All assays were done as triplicate transfections, and all experiments were repeated at least once with similar results.</p></sec><sec id="s4h"><title>TGF&#x003b2; transcriptional reporter assay</title><p>Cells were co-transfected with 4 &#x000b5;g p3TP-Lux (Addgene, Cambridge, MA), a TGF&#x003b2; responsive firefly luciferase reporter containing three consecutive TPA response elements (TREs) and a portion of the plasminogen activator inhibitor 1 (PAI-1) promoter region <xref ref-type="bibr" rid="pone.0023924-Wrana1">[17]</xref>, along with 0.4 &#x000b5;g pRL-TK (Promega, Madison, WI) expressing Renilla luciferase as an internal normalization control. Luciferase activity was assayed 48 hrs after transfection (by Lipofectamine 2000) using the dual luciferase reporter assay system (Promega, Madison, WI). Reporter activity is expressed as the ratio of firefly/Renilla. Assays were done as triplicate transfections, and repeated at least once with similar results.</p></sec><sec id="s4i"><title>Anchorage-independent growth</title><p>A pGIPZ shRNAmir construct targeting <italic>SMURF1</italic> (V2LHS_229724), along with a non-targeting pGIPZ shRNAmir control, were obtained from Open Biosystems (Huntsville, AL). To create stably-transduced AsPC-1 cell pools, lentiviral constructs (along with Trans-lentiviral packaging mix plasmids) were transfected into 293TN producer cells (System Biosciences, Mountain View, CA), and supernatant packaged virus transduced into AsPC-1 cells following the manufacturer's instructions (Open Biosystems' Trans-lentiviral GIPZ packaging protocol). Two days post-infection, 1 &#x000b5;g/ml puromycin (Invitrogen) was added to the culture medium, and cells selected for 14 days. Anchorage independent growth was assayed by colony formation in soft agar. Briefly, 10,000 cells were embedded in a 6-well plate well within a top layer of 0.36&#x00025; agarose in complete media, over a layer of 0.48&#x00025; agarose in complete media. Cells were grown for 14&#x02013;21 days, then visible colonies counted after staining with 0.015&#x00025; Neutral Red solution. Assays were done as triplicate transductions, and repeated at least once with similar results.</p></sec><sec id="s4j"><title>NIH-3T3 focus formation assay</title><p>Full-length human <italic>SMURF1</italic> cDNA expression vector, pcDNA3.1-SMURF1 was a kind gift from Di Chen (University of Rochester Medical Center, Rochester, NY), and the parent vector pcDNA3.1 was purchased from Invitrogen (Carlsbad, CA). A catalytic mutant SMURF1 (C699A) <xref ref-type="bibr" rid="pone.0023924-Wang1">[22]</xref> was engineered using the QuickChange XL II Site-Directed Mutagenesis Kit from Stratagene (La Jolla, CA), with the following mutagenic primers: <named-content content-type="gene">5&#x02032;-CGTGGAGGAGACC<bold>GCC</bold>GGGTTTGCTGTGG -3&#x02032;</named-content> (degenerate, mutated bases denoted by bold text) and <named-content content-type="gene">5&#x02032;-CCACAGCAAACCC<bold>GGC</bold>GGTCTCCTCCACG-3&#x02032;</named-content>. Fifty thousand cells were seeded per 60 mm plate, and 8 &#x000b5;g of plasmid was transfected by Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol. Two days after transfection, cells from each 60 mm plate were re-plated into two 10 cm plates and grown to confluence over 28 days. Visible foci were counted after methanol fixation and Giemsa staining. Assays were done as triplicate transfections, and repeated at least once with similar results.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0023924.s001"><label>Table S1</label><caption><p><bold>siRNA sequences targeting SMURF1.</bold></p><p>(PDF)</p></caption><media xlink:href="pone.0023924.s001.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0023924.s002"><label>Figure S1</label><caption><p><bold>Hs700T cells display TGF&#x003b2;-induced growth inhibition.</bold> Hs700T cells were plated, and then 2 ng/ml TGF&#x003b2; (or vehicle control) added and cell proliferation/viability assayed (by WST-1) daily. Assays were done in triplicate (mean &#x0002b;/&#x02212; 1SD shown); &#x0002a;, <italic>P</italic>&#x0003c;0.05; &#x0002a;&#x0002a;, <italic>P</italic>&#x0003c;0.01; &#x0002a;&#x0002a;&#x0002a;, <italic>P</italic>&#x0003c;0.001 (Student's t-test). Consistent with intact TGF&#x003b2; growth inhibition, no deletions spanning <italic>SMAD4</italic> (244K Agilent CGH array data; not shown) and no point mutations of <italic>SMAD4</italic> (Illumina RNAseq analysis; not shown) were identified.</p><p>(EPS)</p></caption><media xlink:href="pone.0023924.s002.eps" mimetype="application" mime-subtype="postscript"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Ilana Galperin (Stanford Cytogenetics Laboratory) for assistance with FISH analysis, and the members of the Pollack lab for helpful discussions.</p></ack><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by grants from the NIH: CA112016 (J.R.P.), CA09151 (K.A.K.), GI Cancer SPORE CA62924 (A.M.); NIH/NCRR CTSA grant UL1 RR025744 to Stanford Spectrum; and the Lustgarten Foundation (J.R.P.). M.D.B. was supported in part by a Biotechnology overseas associateship from the Department of Biotechnology, Ministry of Science and Technology, Government of India. The authors also thank the family of Margaret Lee and the Sol Goldman Pancreatic Cancer Research Center for supporting the xenografting efforts at Johns Hopkins. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0023924-Jemal1"><label>1</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Cancer statistics, 2009.</article-title>             <source>CA Cancer J Clin</source>             <volume>59</volume>             <fpage>225</fpage>             <lpage>249</lpage>          <pub-id pub-id-type="pmid">19474385</pub-id></element-citation></ref><ref id="pone.0023924-Li1"><label>2</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Xie</surname><given-names>K</given-names></name><name><surname>Wolff</surname><given-names>R</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name></person-group>             <year>2004</year>             <article-title>Pancreatic cancer.</article-title>             <source>Lancet</source>             <volume>363</volume>             <fpage>1049</fpage>             <lpage>1057</lpage>          <pub-id pub-id-type="pmid">15051286</pub-id></element-citation></ref><ref id="pone.0023924-Hezel1"><label>3</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Hezel</surname><given-names>AF</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name><name><surname>Stanger</surname><given-names>BZ</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name><name><surname>Depinho</surname><given-names>RA</given-names></name></person-group>             <year>2006</year>             <article-title>Genetics and biology of pancreatic ductal adenocarcinoma.</article-title>             <source>Genes Dev</source>             <volume>20</volume>             <fpage>1218</fpage>             <lpage>1249</lpage>          <pub-id pub-id-type="pmid">16702400</pub-id></element-citation></ref><ref id="pone.0023924-Hruban1"><label>4</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Schulick</surname><given-names>R</given-names></name><name><surname>Laheru</surname><given-names>D</given-names></name><name><surname>Herman</surname><given-names>J</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Emerging molecular biology of pancreatic cancer.</article-title>             <source>Gastrointest Cancer Res</source>             <volume>2</volume>             <fpage>S10</fpage>             <lpage>15</lpage>          <pub-id pub-id-type="pmid">19343140</pub-id></element-citation></ref><ref id="pone.0023924-Jones1"><label>5</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Leary</surname><given-names>RJ</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.</article-title>             <source>Science</source>             <volume>321</volume>             <fpage>1801</fpage>             <lpage>1806</lpage>          <pub-id pub-id-type="pmid">18772397</pub-id></element-citation></ref><ref id="pone.0023924-Kwei1"><label>6</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Kwei</surname><given-names>KA</given-names></name><name><surname>Bashyam</surname><given-names>MD</given-names></name><name><surname>Kao</surname><given-names>J</given-names></name><name><surname>Ratheesh</surname><given-names>R</given-names></name><name><surname>Reddy</surname><given-names>EC</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer.</article-title>             <source>PLoS Genet</source>             <volume>4</volume>             <fpage>e1000081</fpage>          <pub-id pub-id-type="pmid">18535672</pub-id></element-citation></ref><ref id="pone.0023924-Chen1"><label>7</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Auletta</surname><given-names>T</given-names></name><name><surname>Dovirak</surname><given-names>O</given-names></name><name><surname>Hutter</surname><given-names>C</given-names></name><name><surname>Kuntz</surname><given-names>K</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification.</article-title>             <source>Cancer Biol Ther</source>             <volume>7</volume>          </element-citation></ref><ref id="pone.0023924-Aguirre1"><label>8</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Aguirre</surname><given-names>AJ</given-names></name><name><surname>Brennan</surname><given-names>C</given-names></name><name><surname>Bailey</surname><given-names>G</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>B</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>High-resolution characterization of the pancreatic adenocarcinoma genome.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>101</volume>             <fpage>9067</fpage>             <lpage>9072</lpage>          <pub-id pub-id-type="pmid">15199222</pub-id></element-citation></ref><ref id="pone.0023924-Heidenblad1"><label>9</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Heidenblad</surname><given-names>M</given-names></name><name><surname>Schoenmakers</surname><given-names>EF</given-names></name><name><surname>Jonson</surname><given-names>T</given-names></name><name><surname>Gorunova</surname><given-names>L</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.</article-title>             <source>Cancer Res</source>             <volume>64</volume>             <fpage>3052</fpage>             <lpage>3059</lpage>          <pub-id pub-id-type="pmid">15126341</pub-id></element-citation></ref><ref id="pone.0023924-Holzmann1"><label>10</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Holzmann</surname><given-names>K</given-names></name><name><surname>Kohlhammer</surname><given-names>H</given-names></name><name><surname>Schwaenen</surname><given-names>C</given-names></name><name><surname>Wessendorf</surname><given-names>S</given-names></name><name><surname>Kestler</surname><given-names>HA</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes.</article-title>             <source>Cancer Res</source>             <volume>64</volume>             <fpage>4428</fpage>             <lpage>4433</lpage>          <pub-id pub-id-type="pmid">15231651</pub-id></element-citation></ref><ref id="pone.0023924-Mahlamaki1"><label>11</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Mahlamaki</surname><given-names>EH</given-names></name><name><surname>Kauraniemi</surname><given-names>P</given-names></name><name><surname>Monni</surname><given-names>O</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>Hautaniemi</surname><given-names>S</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer.</article-title>             <source>Neoplasia</source>             <volume>6</volume>             <fpage>432</fpage>             <lpage>439</lpage>          <pub-id pub-id-type="pmid">15548351</pub-id></element-citation></ref><ref id="pone.0023924-Bashyam1"><label>12</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Bashyam</surname><given-names>MD</given-names></name><name><surname>Bair</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Hernandez-Boussard</surname><given-names>T</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.</article-title>             <source>Neoplasia</source>             <volume>7</volume>             <fpage>556</fpage>             <lpage>562</lpage>          <pub-id pub-id-type="pmid">16036106</pub-id></element-citation></ref><ref id="pone.0023924-Loukopoulos1"><label>13</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Loukopoulos</surname><given-names>P</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Katoh</surname><given-names>H</given-names></name><name><surname>Kokubu</surname><given-names>A</given-names></name><name><surname>Sakamoto</surname><given-names>M</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome.</article-title>             <source>Cancer Sci</source>             <volume>98</volume>             <fpage>392</fpage>             <lpage>400</lpage>          <pub-id pub-id-type="pmid">17233815</pub-id></element-citation></ref><ref id="pone.0023924-Pruitt1"><label>14</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Pruitt</surname><given-names>KD</given-names></name><name><surname>Tatusova</surname><given-names>T</given-names></name><name><surname>Maglott</surname><given-names>DR</given-names></name></person-group>             <year>2007</year>             <article-title>NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins.</article-title>             <source>Nucleic Acids Res</source>             <volume>35</volume>             <fpage>D61</fpage>             <lpage>65</lpage>          <pub-id pub-id-type="pmid">17130148</pub-id></element-citation></ref><ref id="pone.0023924-Ebisawa1"><label>15</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Ebisawa</surname><given-names>T</given-names></name><name><surname>Fukuchi</surname><given-names>M</given-names></name><name><surname>Murakami</surname><given-names>G</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><etal/></person-group>             <year>2001</year>             <article-title>Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation.</article-title>             <source>J Biol Chem</source>             <volume>276</volume>             <fpage>12477</fpage>             <lpage>12480</lpage>          <pub-id pub-id-type="pmid">11278251</pub-id></element-citation></ref><ref id="pone.0023924-Moren1"><label>16</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Moren</surname><given-names>A</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name><name><surname>Heldin</surname><given-names>CH</given-names></name><name><surname>Moustakas</surname><given-names>A</given-names></name></person-group>             <year>2005</year>             <article-title>Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases.</article-title>             <source>J Biol Chem</source>             <volume>280</volume>             <fpage>22115</fpage>             <lpage>22123</lpage>          <pub-id pub-id-type="pmid">15817471</pub-id></element-citation></ref><ref id="pone.0023924-Wrana1"><label>17</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Wrana</surname><given-names>JL</given-names></name><name><surname>Attisano</surname><given-names>L</given-names></name><name><surname>Carcamo</surname><given-names>J</given-names></name><name><surname>Zentella</surname><given-names>A</given-names></name><name><surname>Doody</surname><given-names>J</given-names></name><etal/></person-group>             <year>1992</year>             <article-title>TGF beta signals through a heteromeric protein kinase receptor complex.</article-title>             <source>Cell</source>             <volume>71</volume>             <fpage>1003</fpage>             <lpage>1014</lpage>          <pub-id pub-id-type="pmid">1333888</pub-id></element-citation></ref><ref id="pone.0023924-Schutte1"><label>18</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Schutte</surname><given-names>M</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Hedrick</surname><given-names>L</given-names></name><name><surname>Cho</surname><given-names>KR</given-names></name><name><surname>Nadasdy</surname><given-names>GM</given-names></name><etal/></person-group>             <year>1996</year>             <article-title>DPC4 gene in various tumor types.</article-title>             <source>Cancer Res</source>             <volume>56</volume>             <fpage>2527</fpage>             <lpage>2530</lpage>          <pub-id pub-id-type="pmid">8653691</pub-id></element-citation></ref><ref id="pone.0023924-Dai1"><label>19</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Dai</surname><given-names>JL</given-names></name><name><surname>Turnacioglu</surname><given-names>KK</given-names></name><name><surname>Schutte</surname><given-names>M</given-names></name><name><surname>Sugar</surname><given-names>AY</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name></person-group>             <year>1998</year>             <article-title>Dpc4 transcriptional activation and dysfunction in cancer cells.</article-title>             <source>Cancer Res</source>             <volume>58</volume>             <fpage>4592</fpage>             <lpage>4597</lpage>          <pub-id pub-id-type="pmid">9788608</pub-id></element-citation></ref><ref id="pone.0023924-Wan1"><label>20</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Jhala</surname><given-names>NC</given-names></name><name><surname>Tytler</surname><given-names>EM</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>SCF(beta-TrCP1) controls Smad4 protein stability in pancreatic cancer cells.</article-title>             <source>Am J Pathol</source>             <volume>166</volume>             <fpage>1379</fpage>             <lpage>1392</lpage>          <pub-id pub-id-type="pmid">15855639</pub-id></element-citation></ref><ref id="pone.0023924-Hahn1"><label>21</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Hahn</surname><given-names>SA</given-names></name><name><surname>Schutte</surname><given-names>M</given-names></name><name><surname>Hoque</surname><given-names>AT</given-names></name><name><surname>Moskaluk</surname><given-names>CA</given-names></name><name><surname>da Costa</surname><given-names>LT</given-names></name><etal/></person-group>             <year>1996</year>             <article-title>DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.</article-title>             <source>Science</source>             <volume>271</volume>             <fpage>350</fpage>             <lpage>353</lpage>          <pub-id pub-id-type="pmid">8553070</pub-id></element-citation></ref><ref id="pone.0023924-Wang1"><label>22</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Wang</surname><given-names>HR</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ozdamar</surname><given-names>B</given-names></name><name><surname>Ogunjimi</surname><given-names>AA</given-names></name><name><surname>Alexandrova</surname><given-names>E</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Regulation of cell polarity and protrusion formation by targeting RhoA for degradation.</article-title>             <source>Science</source>             <volume>302</volume>             <fpage>1775</fpage>             <lpage>1779</lpage>          <pub-id pub-id-type="pmid">14657501</pub-id></element-citation></ref><ref id="pone.0023924-Massague1"><label>23</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Massague</surname><given-names>J</given-names></name></person-group>             <year>2008</year>             <article-title>TGFbeta in Cancer.</article-title>             <source>Cell</source>             <volume>134</volume>             <fpage>215</fpage>             <lpage>230</lpage>          <pub-id pub-id-type="pmid">18662538</pub-id></element-citation></ref><ref id="pone.0023924-Ozdamar1"><label>24</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Ozdamar</surname><given-names>B</given-names></name><name><surname>Bose</surname><given-names>R</given-names></name><name><surname>Barrios-Rodiles</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>HR</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity.</article-title>             <source>Science</source>             <volume>307</volume>             <fpage>1603</fpage>             <lpage>1609</lpage>          <pub-id pub-id-type="pmid">15761148</pub-id></element-citation></ref><ref id="pone.0023924-Huang1"><label>25</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Rajfur</surname><given-names>Z</given-names></name><name><surname>Yousefi</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Jacobson</surname><given-names>K</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Talin phosphorylation by Cdk5 regulates Smurf1-mediated talin head ubiquitylation and cell migration.</article-title>             <source>Nat Cell Biol</source>             <volume>11</volume>             <fpage>624</fpage>             <lpage>630</lpage>          <pub-id pub-id-type="pmid">19363486</pub-id></element-citation></ref><ref id="pone.0023924-Suzuki1"><label>26</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Murakami</surname><given-names>Y</given-names></name><name><surname>Horii</surname><given-names>A</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.</article-title>             <source>Cancer Sci</source>             <volume>99</volume>             <fpage>986</fpage>             <lpage>994</lpage>          <pub-id pub-id-type="pmid">18380791</pub-id></element-citation></ref><ref id="pone.0023924-Sledz1"><label>27</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Sledz</surname><given-names>CA</given-names></name><name><surname>Holko</surname><given-names>M</given-names></name><name><surname>de Veer</surname><given-names>MJ</given-names></name><name><surname>Silverman</surname><given-names>RH</given-names></name><name><surname>Williams</surname><given-names>BR</given-names></name></person-group>             <year>2003</year>             <article-title>Activation of the interferon system by short-interfering RNAs.</article-title>             <source>Nat Cell Biol</source>             <volume>5</volume>             <fpage>834</fpage>             <lpage>839</lpage>          <pub-id pub-id-type="pmid">12942087</pub-id></element-citation></ref><ref id="pone.0023924-Laurila1"><label>28</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Laurila</surname><given-names>E</given-names></name><name><surname>Savinainen</surname><given-names>K</given-names></name><name><surname>Kuuselo</surname><given-names>R</given-names></name><name><surname>Karhu</surname><given-names>R</given-names></name><name><surname>Kallioniemi</surname><given-names>A</given-names></name></person-group>             <year>2009</year>             <article-title>Characterization of the 7q21-q22 amplicon identifies ARPC1A, a subunit of the Arp2/3 complex, as a regulator of cell migration and invasion in pancreatic cancer.</article-title>             <source>Genes Chromosomes Cancer</source>             <volume>48</volume>             <fpage>330</fpage>             <lpage>339</lpage>          <pub-id pub-id-type="pmid">19145645</pub-id></element-citation></ref><ref id="pone.0023924-Kao1"><label>29</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Kao</surname><given-names>J</given-names></name><name><surname>Pollack</surname><given-names>JR</given-names></name></person-group>             <year>2006</year>             <article-title>RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes.</article-title>             <source>Genes Chromosomes Cancer</source>             <volume>45</volume>             <fpage>761</fpage>             <lpage>769</lpage>          <pub-id pub-id-type="pmid">16708353</pub-id></element-citation></ref><ref id="pone.0023924-Chen2"><label>30</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Matesic</surname><given-names>LE</given-names></name></person-group>             <year>2007</year>             <article-title>The Nedd4-like family of E3 ubiquitin ligases and cancer.</article-title>             <source>Cancer Metastasis Rev</source>             <volume>26</volume>             <fpage>587</fpage>             <lpage>604</lpage>          <pub-id pub-id-type="pmid">17726579</pub-id></element-citation></ref><ref id="pone.0023924-Guedat1"><label>31</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Guedat</surname><given-names>P</given-names></name><name><surname>Colland</surname><given-names>F</given-names></name></person-group>             <year>2007</year>             <article-title>Patented small molecule inhibitors in the ubiquitin proteasome system.</article-title>             <source>BMC Biochem</source>             <volume>8</volume>             <issue>Suppl 1</issue>             <fpage>S14</fpage>          <pub-id pub-id-type="pmid">18047738</pub-id></element-citation></ref><ref id="pone.0023924-Hahn2"><label>32</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Hahn</surname><given-names>SA</given-names></name><name><surname>Seymour</surname><given-names>AB</given-names></name><name><surname>Hoque</surname><given-names>AT</given-names></name><name><surname>Schutte</surname><given-names>M</given-names></name><name><surname>da Costa</surname><given-names>LT</given-names></name><etal/></person-group>             <year>1995</year>             <article-title>Allelotype of pancreatic adenocarcinoma using xenograft enrichment.</article-title>             <source>Cancer Res</source>             <volume>55</volume>             <fpage>4670</fpage>             <lpage>4675</lpage>          <pub-id pub-id-type="pmid">7553647</pub-id></element-citation></ref><ref id="pone.0023924-Pollack1"><label>33</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Pollack</surname><given-names>JR</given-names></name><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Rees</surname><given-names>CA</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>99</volume>             <fpage>12963</fpage>             <lpage>12968</lpage>          <pub-id pub-id-type="pmid">12297621</pub-id></element-citation></ref><ref id="pone.0023924-Tibshirani1"><label>34</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name></person-group>             <year>2008</year>             <article-title>Spatial smoothing and hot spot detection for CGH data using the fused lasso.</article-title>             <source>Biostatistics</source>             <volume>9</volume>             <fpage>18</fpage>             <lpage>29</lpage>          <pub-id pub-id-type="pmid">17513312</pub-id></element-citation></ref><ref id="pone.0023924-Perou1"><label>35</label><element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><etal/></person-group>             <year>2000</year>             <article-title>Molecular portraits of human breast tumours.</article-title>             <source>Nature</source>             <volume>406</volume>             <fpage>747</fpage>             <lpage>752</lpage>          <pub-id pub-id-type="pmid">10963602</pub-id></element-citation></ref></ref-list></back></article>